Clinical Trials
36 trialsA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ruijin Hospital
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
The First Affiliated Hospital with Nanjing Medical University
Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Shanghai Cell Therapy Group Co.,Ltd
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
CAR-T，MTD
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
Zhejiang University
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
AvR-CHOP
Austin Health
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
University of Chicago
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Guangdong Second Provincial General Hospital
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Changhai Hospital
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
Xuzhou Medical University
UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
Beijing Tsinghua Chang Gung Hospital
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
Hebei Yanda Ludaopei Hospital
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
iCell Gene Therapeutics
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
iCell Gene Therapeutics
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Institute of Hematology & Blood Diseases Hospital, China
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
PREVAIL
Lund University Hospital
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
University of California, San Francisco